BioVector® WM1799 人皮肤黑色素瘤细胞系 / BioVector® WM1799 Human Skin Melanoma Cell Line

通用定义 / General Definition:BioVector® WM1799 是一种源自人皮肤黑色素瘤 (Melanoma) 的原发性肿瘤细胞系。该细胞系处于黑色素瘤发展的径向生长期 (Radial Growth Phase, RGP)。在黑色素瘤的演进过程中，RGP 代表了早期阶段，此时肿瘤主要局限于表皮层内向水平方向扩张。WM1799 特别具有科研价值，因为它携带 NRAS Q61L 突变，且其 BRAF 动基因为野生型 (WT)。这使其成为研究非 BRAF 突变型黑色素瘤发病机制、NRAS 驱动的信号传导通路以及开发针对性靶向疗法的关键模型。

BioVector® WM1799 is a human skin Melanoma cell line derived from a primary tumor. It represents the Radial Growth Phase (RGP) of melanoma development. In the progression of melanoma, the RGP signifies an early stage where the tumor expands horizontally, primarily confined to the epidermis. WM1799 is particularly valuable for research as it carries the NRAS Q61L mutation while being BRAF Wild-Type (WT). This makes it a critical model for studying the pathogenesis of non-BRAF mutated melanoma, NRAS-driven signaling pathways, and the development of targeted therapies for this specific genetic subgroup.

BioVector® WM1799 技术说明书 (Technical Datasheet)

中文版说明书 (Chinese Datasheet)

1. 产品基本信息

• 产品名称： BioVector® WM1799 人皮肤黑色素瘤细胞

• 组织来源： 皮肤 (Skin)

• 疾病背景： 黑色素瘤 (原发灶，径向生长期)

• 生长特性： 贴壁生长

• 细胞形态： 上皮样或纺锤形，具有黑色素瘤早期的形态特征。

2. 培养条件

• 基础培养基： BioVector® W489 培养基 或 MCDB153/L15 (4:1) 混合培养基。

• 血清添加： 2% BioVector® 优质胎牛血清 (FBS)。

• 关键添加剂： 5 $\mu$g/mL 胰岛素 (Insulin)。

• 培养环境： 37 摄氏度，5% CO2

• 传代比例： 1:2 至 1:3；由于 RGP 期细胞生长相对缓慢，建议在细胞汇合度达到 85% 时进行传代。

3. 细胞应用

• 突变特异性研究： 探索 NRAS Q61L 突变对 PI3K/Akt 和 MAPK 通路的特异性激活作用。

• 早期演变模拟： 研究黑色素瘤从径向生长期向垂直生长期 (VGP) 转化的分子开关。

• 药物筛选： 筛选针对 NRAS 突变型黑色素瘤的 MEK 抑制剂或联合用药方案。

4. 注意事项

• 生长周期： 相比于晚期黑色素瘤细胞系（如 WM88），WM1799 的倍增时间可能较长，需耐心维护。

• 基因组稳定性： NRAS 突变是其核心特征，建议在实验关键节点通过测序确认突变状态。

English Datasheet

1. General Product Information

• Product Name: BioVector® WM1799 Human Skin Melanoma Cell Line

• Tissue Source: Skin

• Disease Context: Melanoma (Primary tumor, Radial Growth Phase)

• Growth Properties: Adherent

• Morphology: Epithelial-like or spindle-shaped, reflecting early-stage melanoma morphology.

2. Culture Conditions

• Basal Medium: BioVector® W489 Medium or MCDB153/L15 (4:1) mixture.

• Serum Supplement: 2% BioVector® Fetal Bovine Serum (FBS).

• Supplements: 5 $\mu$g/mL Insulin.

• Incubation: 37 degrees Celsius, 5% CO2.

• Subculturing: 1:2 to 1:3 ratio; as RGP cells typically proliferate more slowly, subculture when cells reach 85% confluence.

3. Applications

• Mutation-Specific Research: Exploring the specific activation of PI3K/Akt and MAPK pathways by the NRAS Q61L mutation.

• Early Progression Modeling: Investigating the molecular "switches" involved in the transition from Radial Growth Phase to Vertical Growth Phase (VGP).

• Drug Discovery: Screening MEK inhibitors or combination therapies specifically for NRAS-mutant melanoma subtypes.

4. Key Usage Notes

• Proliferation Rate: Compared to advanced melanoma lines (like WM88), WM1799 may have a longer doubling time; consistent monitoring is required.

• Genomic Integrity: The NRAS mutation is a defining characteristic; BioVector® recommends verifying the mutation status via sequencing at critical experimental junctures.

注意 / Note: BioVector® WM1799 应在生物安全二级 (BSL-2) 条件下操作。为保持其早期生长期表型，建议避免使用高浓度血清。

BioVector® WM1799 should be handled under Biosafety Level 2 (BSL-2) conditions. To maintain its early growth phase phenotype, BioVector® advises against the use of high-concentration serum.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

E-mail: BioVector@163.com

http://www.biovector.net